Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2

NCT04969991 is registered in ClinicalTrials.gov with Ophirex, Inc. as lead sponsor.

NCT NCT04969991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04969991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2
Lead sponsor
Ophirex, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2021
Completion date
November 22, 2022
Enrollment
18 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019, disease caused by severe acute respiratory syndrome coronavirus 2